BGM - BGM • Financials

BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
09/2017	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
09/2018	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
09/2019	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
09/2020	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
09/2021	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
09/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
09/2023	46	-1	-	L	L	43	L	-22	-	0	-4	-3	-3	0	-2	L	-
09/2024	25	1	-	L	L	43	L	-18	-	1	-4	-0	-3	0	0	-	-
09/2025	38	-11	-	L	L	391	L	-9	-	-13	-2	3	-15	0	0	-	-

To see all financials—including updated, you must be Premium.